The purpose of this study is to test the safety and effectiveness of the study drug, avatrombopag, in subjects with thrombocytopenia undergoing an operation. Patients will receive either 60mg or 80mg of avatrombopag once daily by mouth for 5 days prior to surgeryMore
Adult, undergoing surgery to critical site (i.e. spine), low platelet count prior to surgery
Detailed Eligibility: Can not have: history of blood clots, be on anticoagulant or antiplatelet therapy prior to surgery, alcohol dependence, active infection, significant cardiovascular disease, current malignancy, hepatic encephalopathy or hepatocellular carcinoma.
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
University of Colorado Hospital
Peter Witt, MD
Protocol Number: 18-0546
More information available at ClinicalTrials.gov: NCT03326843
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers